Trav39: A Potential Drug Target and Biomarker (G28642)

Target Name: TRAV39

NCBI ID: G28642

TRAV39

Other Name(s): TCRAV27S1 | TCRAV39S1 | T cell receptor alpha variable 39

Trav39: A Potential Drug Target and Biomarker

Trav39 (TCRAV27S1) is a drug target (or biomarker) that has been identified and targeted by researchers. Trav39 is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is a member of the T cell receptor (TCR) family, which is a protein that is involved in the immune system.

One of the main functions of Trav39 is its role in cell signaling. It is a co-factor for the protein Pyknotide, which plays a role in regulating the activity of DNA-protein binding proteins. This protein is also known as p16, and it is a key regulator of the cell cycle.

Research has shown that Trav39 is involved in many different processes in the body, including cell growth, differentiation, and survival. It is also involved in the development and progression of various diseases, including cancer.

One of the most promising aspects of Trav39 is its potential as a drug target. Researchers have identified several potential drug-target interactions with Trav39, including its role in cell signaling, its expression in various tissues, and its involvement in disease.

In addition to its potential as a drug target, Trav39 is also a potential biomarker. Its expression has been shown to be elevated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that Trav39 may be a useful biomarker for these diseases.

Overall, Trav39 is a protein that has significant potential as a drug target and biomarker. Further research is needed to fully understand its role in the immune system and its potential as a therapeutic agent.

Protein Name: T Cell Receptor Alpha Variable 39

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets